49 related articles for article (PubMed ID: 18187929)
1. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
2. Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.
Schwartz L; Spitsin SV; Meshki J; Tuluc F; Douglas SD; Wolfe JH
J Neurovirol; 2013 Jun; 19(3):219-27. PubMed ID: 23765222
[TBL] [Abstract][Full Text] [Related]
3. Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages.
Wang X; Douglas SD; Song L; Wang YJ; Ho WZ
J Neuroimmune Pharmacol; 2008 Dec; 3(4):257-64. PubMed ID: 18654860
[TBL] [Abstract][Full Text] [Related]
4. The two NK-1 binding sites correspond to distinct, independent, and non-interconvertible receptor conformational states as confirmed by plasmon-waveguide resonance spectroscopy.
Alves ID; Delaroche D; Mouillac B; Salamon Z; Tollin G; Hruby VJ; Lavielle S; Sagan S
Biochemistry; 2006 Apr; 45(16):5309-18. PubMed ID: 16618119
[TBL] [Abstract][Full Text] [Related]
5. Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.
Vink R; Nimmo A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542509
[TBL] [Abstract][Full Text] [Related]
6. The Use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
Martín-García D; Téllez T; Redondo M; García-Aranda M
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37861026
[TBL] [Abstract][Full Text] [Related]
7. Neurokinin receptors and their implications in various autoimmune diseases.
Mishra A; Lal G
Curr Res Immunol; 2021; 2():66-78. PubMed ID: 35492389
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Antimalarial Activity of 1,4-Disubstituted Piperidine Derivatives.
Seck R; Gassama A; Cojean S; Cavé C
Molecules; 2020 Jan; 25(2):. PubMed ID: 31940857
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
[TBL] [Abstract][Full Text] [Related]
10. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
11. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
12. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.
Tattersall FD; Rycroft W; Cumberbatch M; Mason G; Tye S; Williamson DJ; Hale JJ; Mills SG; Finke PE; MacCoss M; Sadowski S; Ber E; Cascieri M; Hill RG; MacIntyre DE; Hargreaves RJ
Neuropharmacology; 2000 Feb; 39(4):652-63. PubMed ID: 10728886
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
